8-K: ZIVO BIOSCIENCE Shareholders Elect Directors, Ratify Auditor, and Approve Executive Compensation at Annual Meeting

ZIVO BIOSCIENCE, INC. announced that its shareholders approved all three proposals at the annual meeting held on June 9, 2025, including the election of two Class III directors, the ratification of its independent public accounting firm, and the advisory approval of executive compensation.

Summary

• At the annual meeting of shareholders held on June 9, 2025, ZIVO BIOSCIENCE, INC. shareholders elected two Class III directors, John B. Payne and Alison A. Cornell, each to serve a three-year term until the 2028 annual meeting.
• Shareholders ratified the appointment of BDO USA, P.C. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The compensation of the company's named executive officers was approved on an advisory basis by shareholders.
• A total of 2,507,058 shares of common stock were present at the meeting, representing approximately 66.11% of the shares outstanding as of the record date.
• All three proposals presented to the shareholders were approved according to the final vote results.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposals passed as expected, indicating stable corporate governance and shareholder alignment with management's recommendations. There are no negative surprises or adverse events reported.

Positives

• All three proposals, including director elections, auditor ratification, and executive compensation approval, passed successfully, indicating strong shareholder support for the company's governance and management.
• A high shareholder participation rate of approximately 66.11% of outstanding shares demonstrates active engagement from the investor base.
• The election of two Class III directors for three-year terms provides stability and continuity to the Board of Directors until 2028.

Future Outlook

The election of Class III directors for terms extending until the 2028 annual meeting provides a stable leadership structure for the coming years. The ratification of the independent auditor for the fiscal year ending December 31, 2025, ensures continuity in financial oversight.

Industry Context

This filing is a routine corporate governance update, typical for publicly traded companies following their annual shareholder meetings. It reflects standard practices in shareholder engagement and board oversight within the biotechnology or life sciences industry, where ZIVO BIOSCIENCE operates.

Comparison to Industry Standards

• The shareholder participation rate of 66.11% is generally considered healthy for an annual meeting, indicating reasonable engagement compared to typical averages for small-cap companies, which can vary widely but often fall between 50-70%.
• The unanimous approval of all management-recommended proposals aligns with common outcomes for well-managed companies where shareholder interests are perceived to be aligned with the board's recommendations.
• The election of directors for three-year staggered terms is a common corporate governance practice aimed at promoting board stability and continuity, consistent with many public companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The approval of all proposals indicates alignment between shareholders and the company's management and board, potentially fostering confidence in the company's governance.
• Employees: The advisory approval of executive compensation provides clarity on the remuneration framework for key management personnel.
• Creditors: Stable corporate governance and auditor ratification can provide assurance regarding the company's financial oversight and reporting integrity.

Next Steps

• The newly elected Class III directors, John B. Payne and Alison A. Cornell, will serve their three-year terms until the 2028 annual meeting of shareholders.
• BDO USA, P.C. will continue as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

Keywords

ZIVO BIOSCIENCE, Shareholder Meeting, Corporate Governance, Board of Directors, Auditor Ratification, Executive Compensation, SEC Filing, 8-K, Voting Results